These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

796 related items for PubMed ID: 30327931

  • 21. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.
    Cochrane Database Syst Rev; 2017 Apr 25; 4(4):CD012200. PubMed ID: 28440858
    [Abstract] [Full Text] [Related]

  • 22. Teriflunomide for multiple sclerosis.
    He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S.
    Cochrane Database Syst Rev; 2012 Dec 12; 12():CD009882. PubMed ID: 23235682
    [Abstract] [Full Text] [Related]

  • 23. Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison.
    Chan A, Cutter G, Fox RJ, Xiao J, Lewin JB, Edwards MR.
    J Comp Eff Res; 2017 Jun 12; 6(4):313-323. PubMed ID: 28350241
    [Abstract] [Full Text] [Related]

  • 24. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
    Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G.
    Adv Ther; 2014 Nov 12; 31(11):1134-54. PubMed ID: 25414048
    [Abstract] [Full Text] [Related]

  • 25. Persistence to oral disease-modifying therapies in multiple sclerosis patients.
    Lattanzi S, Danni M, Taffi R, Cerqua R, Carlini G, Pulcini A, Provinciali L, Silvestrini M.
    J Neurol; 2017 Nov 12; 264(11):2325-2329. PubMed ID: 28831550
    [Abstract] [Full Text] [Related]

  • 26. A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.
    Hillert J, Tsai JA, Nouhi M, Glaser A, Spelman T.
    Mult Scler; 2022 Feb 12; 28(2):237-246. PubMed ID: 34080926
    [Abstract] [Full Text] [Related]

  • 27. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
    Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM.
    J Neurol Sci; 2019 Dec 15; 407():116498. PubMed ID: 31644992
    [Abstract] [Full Text] [Related]

  • 28. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
    Gil-Bernal R, González-Caballero JL, Espinosa-Rosso R, Gómez-Gómez C.
    Sci Rep; 2021 Jun 15; 11(1):12533. PubMed ID: 34131191
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C, Bramanti P, Mazzon E.
    Drug Des Devel Ther; 2017 Jun 15; 11():2193-2207. PubMed ID: 28814828
    [Abstract] [Full Text] [Related]

  • 31. Comparative effectiveness and safety of ozanimod versus other oral DMTs in relapsing-remitting multiple sclerosis: a synthesis of matching-adjusted indirect comparisons.
    Paul D, Swallow E, Patterson-Lomba O, Branchcomb T, N'Dri L, Gomez-Lievano A, Liu J, Dua A, McGinley M.
    Ther Adv Neurol Disord; 2024 Jun 15; 17():17562864241237856. PubMed ID: 38855023
    [Abstract] [Full Text] [Related]

  • 32. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, Tomassini V, Wardle M, Pickersgill T, Robertson N, Tallantyre E.
    JAMA Neurol; 2019 May 01; 76(5):536-541. PubMed ID: 30776055
    [Abstract] [Full Text] [Related]

  • 33. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V.
    J Manag Care Spec Pharm; 2017 Aug 01; 23(8):844-852. PubMed ID: 28737986
    [Abstract] [Full Text] [Related]

  • 34. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Hass S, Thangavelu K, Leist TP.
    Mult Scler Relat Disord; 2016 Nov 01; 10():204-212. PubMed ID: 27919491
    [Abstract] [Full Text] [Related]

  • 35. Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.
    Spelman T, Frisell T, Piehl F, Hillert J.
    Mult Scler; 2018 Jul 01; 24(8):1087-1095. PubMed ID: 28649912
    [Abstract] [Full Text] [Related]

  • 36. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
    Su W, Kansal A, Vicente C, Deniz B, Sarda S.
    J Med Econ; 2016 Jul 01; 19(7):718-27. PubMed ID: 27080475
    [Abstract] [Full Text] [Related]

  • 37. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
    Boz C, Terzi M, Özer B, Turkoglu R, Karabudak R, Efendi H, Soysal A, Sevim S, Altintas A, Kurne A, Akçalı A, Akman G, Yüceyar N, Balcı BP, Ekmekci Ö, Karahan SZ, Demirkıran M, Altunrende B, Turan ÖF, Gökçen GözübatıkÇelik, Kale N, Köseoğlu M, Ozakbas S.
    Mult Scler Relat Disord; 2019 Nov 01; 36():101376. PubMed ID: 31473488
    [Abstract] [Full Text] [Related]

  • 38. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
    Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, Gasperini C, Marfia GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M.
    Neurology; 2018 Jul 10; 91(2):e153-e161. PubMed ID: 29875218
    [Abstract] [Full Text] [Related]

  • 39. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH, Wakefield RA.
    Am J Health Syst Pharm; 2015 Jan 01; 72(1):25-38. PubMed ID: 25511835
    [Abstract] [Full Text] [Related]

  • 40. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
    Pistono C, Osera C, Boiocchi C, Mallucci G, Cuccia M, Bergamaschi R, Pascale A.
    Pharmacol Res; 2017 Jun 01; 120():279-293. PubMed ID: 28396093
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.